zimmer biomet see earli fruit turnaround
page full analyst note jul
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim apr
price data jul
rate updat jul
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
zimmer leader hip knee reconstruct enjoy fruit
wide econom moat addit smaller competitor
biomet zimmer undisput king hip knee implant
far expect favor demograph includ age
babi boomer rise obes fuel solid demand large-joint
replac off-set price declin howev zimmer
plagu pitfal last two year includ
integr issu suppli challeng qualiti concern
caught attent food drug administr
new manag tackl issu expect
meaning improv next year
zimmer benefit close relationship orthoped
surgeon make brand choic high switch cost
high-touch servic keep surgeon close tie primari
vendor surgeon bring enough profit procedur
keep hospit administr bay close relationship
vendor loyalti also explain market share shift orthoped
implant glacial best long zimmer launch
compar technolog within year rival remain
strong competit posit nevertheless think surgeon
influenc inevit erod practic medicin chang
respons healthcar reform long term
difficult surgeon run privat practic profit
open employ hospit
think grow emphasi payer hospit
compar effect cost-effect make
condit tougher zimmer rival natur
orthoped innov tend evolutionari rather
revolutionari also less common orthoped innov
tap untreat patient pool unmet need
strategi cardiac devic maker pursu success
difficulti ethic issu surround random control
trial orthoped also weaken zimmer posit
press premium price think achiev meaning
innov orthoped implant challeng
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
zimmer biomet design manufactur market orthoped
reconstruct implant well suppli surgic equip
orthoped surgeri acquisit centerpuls biomet
zimmer hold lead share reconstruct market
unit state europ japan roughli total revenu deriv
sale larg joint anoth come extrem trauma
remain portion primarili relat spine dental product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
zimmer biomet see earli fruit turnaround
pleas see zimmer biomet turnaround begin
demonstr real sign goos firm back growth
second quarter anticip moder rais
fair valu estim reflect increas confid
zimmer biomet grow market rate hip
knee aid introduct rosa robot
relat product pull-through also expect spend
remedi effort warsaw north campu plant
weigh profit eas
high switch cost orthoped surgeon like
keep brand firm
gener resolv inventori issu begun
commerci rosa robot think sale rep
surgeon interest increas use devic
even though rival outpac market
knee mako robot second quarter
constant currenc year year think
notabl sever reason first firm
strongest knee perform last quarter
second look market
signific impact mako placement zimmer
biomet america knee growth noth sneez
though trail stryker quarterli rise zimmer
fairli consist rel perform knee held
steadi across last six quarter lead us believ
firm done better job hang onto
surgeon inroad competit account
like come primarili expens
rosa robot place could put pressur
 js knee launch orthotaxi robot
placement rosa robot believ instal base
extrem small first six month soft
launch expect strong steadi uptak
midterm weve seen stryker mako experi
feasibl hit pace placement quarter
within year though earli day wise allow
time newli train surgeon becom facil
robot obtain procedur success consid
zimmer biomet pool train surgeon significantli
larger view pace placement
emin feasibl especi given hospit begun
view orthoped robot credibl tool attract
patient addit think rosa key featur
includ dynam guidanc system automat
adjust bodi movement real time softwar
produc imag plain-vanilla x-ray plan
purpos elimin need patient exposur
ct radiationar differenti attract surgeon
hold steadi fair valu estim per
share reflect optimist project
oper leverag time frame despit
near-term turbul relat regulatori issu
manag chang think zimmer biomet wide
econom moat remain intact sourc moat
chang materi underli dynam
orthoped market remain balanc favor
manufactur follow acquisit biomet take
temper view combin firm prospect
work address current oper regulatori
issu project averag annual revenu growth
zimmer biomet trail orthoped
market growth mid-single-digit growth oper
incom taper
would put profit slightli short zimmer
histor level
although manag close-mouth quarterli
condit favor large-joint implant
volum patient feel financi stabl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
incorpor robust knee hip growth thank
better-than-expect volum gain fuel uptak
rosa robot smaller price declin result growth
match market also assum averag
annual growth extrem trauma along
mid-single-digit growth dental surgic product
zimmer abl resolv oper
regulatori issu bring consolid oper margin
back line past peak level
bearish scenario estim zimmer worth
per share scenario see anem market adopt
rosa robot weaker large-joint implant product
pull-through declin
price almost
complet off-set volum gain hip knee trauma
extrem dental surgic product remain
flat-to-declin zimmer oper margin peak
thank unfavor price
wholli off-set lower sale market spend
zimmer wide econom moat stem two major
sourc first substanti switch cost
orthoped surgeon extens instrument tool
set use prepar bone instal implant specif
compani learn curv becom profici
use one compani instrument signific
addit rel specialist orthoped
surgeon skill experi play outsiz role
clinic outcom patient issu leav
train master multipl
instrument system especi procedur volum
low maintain high surgic facil one
system surgeon prefer certain vendor
stretch back day resid train research
found surgeon stick prefer vendor
sale rep year use vendor
approxim orthoped procedur
time switch anoth instrument system
enough undergo joint-replac procedur
project low-single-digit growth knee hip
base case estim averag
annual volum growth knee hip respect
product line expect current low-single-digit
annual declin price continu project
smaller extrem categori continu grow
mid-single-digit clip forc innov new product
also help zimmer fend price pressur
market
assum zimmer cost equiti equival
rate return expect investor demand
averag sensit econom cycl rel
base averag volatil cash flow
extens orthoped product portfolio rate zimmer
uncertainti medium
bull case put zimmer valu per share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
would requir take time train develop
relationship new sale rep work less effici
earli period master anoth vendor tool
possibl rais risk patient reduc
number procedur incom surgeon
dynam explain market share among six top
orthoped implant maker remain remark steadi
orthoped surgeon may perform hip
replac knee replac year
sale rep provid valuabl servic small group
high-volum surgeon may perform five knee
replac day less need train
sale rep surgeon may wish hire nurs
handl procedur prepar
intellectu properti protect product portfolio
character evolutionari chang
technolog new gener product reli
intellectu properti establish earlier iter
devic follow chang patent law introduc
 switch first-inventor-to-fil
system previous first-to-inv system
think chang favor moat larger
inventor file applic soon possibl inventor
also need provid detail applic order
head competitor may block improv patent
futur gener product new law also
mandat opposit review patent
grant result challeng patent
think firm like zimmer support extens legal
team better posit take advantag
new law file comprehens patent applic
timelin mount complex
patent grant
think anoth intang asset relationship
sale rep surgeon
medic devic equip orthoped sale rep play
critic role surgeon sale rep present
everi procedur teach surgeon use tool
kit prepar select instrument
right size sequenc procedur
think zimmer moat trend remain stabl despit
near-term turbul due regulatori issu inventori
glitch new manag grasp rein think
surgeon favor zimmer biomet product
past like give firm leeway address
obstacl disrupt reliabl suppli
product brand histor fall behind key
orthoped competitor even year
necessarili perman impair underli busi
recent competit activ around large-joint
replac driven indic expans
robot system includ total knee replac
mako robot smith nephew navio robot
reassur zimmer biomet acquisit rosa
robot firm pursuit total knee replac
indic put firm strong posit play
catch next month rosa robot give
zimmer biomet leg orthoped stalwart johnson
johnson reluct acquir type
although larger reimburs environ remain
tough expect on-going price pressur zimmer
biomet remain strong competit posit
combin compani access largest pool
surgeon train instrumentationestim
roughli total hip knee surgeon think
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
eager go along chang think
weaken surgeon influenc autonomi take
place gradual long time frame unlik primary-car
practition cardiologist repres
highest proport specialist sign
hospit healthcar system employe orthoped
surgeon repres last holdout privat practic
current orthoped surgeon salari
hospit system half still privat practic
long haul proport employe orthoped
surgeon undoubtedli grow gener
chang consid current rate convers
take year orthoped surgeon reach
level hospit employ cardiologist
alreadi reach meantim orthoped surgeon
remain highli independ enjoy autonomi
increas incom fee-for-servic framework resist
hospit effort limit brand choic mani
attempt hospit made rein
analysi team formulari model -- mostli fail
face healthcar reform stake hospit
rais continu chip away
issu pilot account care organ
bundl reimburs grow
pressur orthoped surgeon
accommod
cost-contain measur could limit brand
choic medicar continu cut physician fee
joint replac orthoped surgeon may decid
better hospit employe would
acceler consolid brand choic hand
administr
size combin surgeon pool along high
switch cost orthoped virtual guarante
zimmer nearli everi hospit vendor list
replac medicar
payer whittl away reimburs joint
reconstruct procedur demand expect
rise first babi boomer reach key age window
reimburs surgeon hip knee replac
procedur introduc bundl payment hip/kne
replac implant account
approxim half procedur reimburs
medicar zimmer find much difficult justifi
price increas reimburs remain pressur
erod reimburs also mean orthoped
procedur histor profit-cent
hospit less profit also suggest
orthoped surgeon could less influenc
hospit institut shift cardiovascular
neurosurgeri outsiz profit contribut
longer term zimmer histor relianc
surgeon relationship could serious weaken firm
econom moat triangul relationship among
physician hospit payer zimmer biomet
histor thrown lot surgeon make
brand choic histor posit
align zimmer surgeon typic free
agent could practic hospit long
orthoped surgeon brought profit procedur
hospit held sway relationship
hospit defer orthoped procedur
profit hospit
greater pressur manag profit hospit
administr assert bring cost
includ implant control
howev suggest orthoped surgeon
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oth introduct gel-on zimmer single-inject
hyaluron acid product complement firm
broader rang knee implant orthoped
surgeon use gel-on treat mild
oth scarciti high-qual compar effect
research data make difficult orthoped
compani secur premium price time
payer hospit rais bar cost-
oorthoped surgeon often resist effort hospit
health system limit autonomi brand
choic one major factor contribut
consist failur program put forth
provid
ozimm amass impress portfolio
patent own control approxim
issu patent applic world-wide
opportun custom also mean
complic
 could put pressur zimmer
continu shoulder consider cost high-
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
follow acquisit biomet firm
consist de-lever -- pay debt
billion end anticip substanti
de-lever decemb gross debt
stood billion roughli time trail
adjust ebitda consider improv sinc
acquisit biomet left firm
debt/adjust ebitda time expect zimmer
biomet hit net debt/adjust ebitda
end year estim would put
leverag close manag goal gross
debt/ebitda time
base averag volatil cash flow
extens orthoped product portfolio rate zimmer
biomet uncertainti medium zimmer biomet
near-term risk bound regulatori infract
fda document number qualiti control
issu seriou perspect issu
resolv time manner product may
risk fda decid interven hold market
product pipelin candid regulatori review
zimmer biomet taken step restor adequ
inventori level order sale rep effect
appeal orthoped surgeon slip-up could
slow sale greatest long-term strateg
risk zimmer manag team come
grip chang orthoped environ
although chang unfold slowli write
wall bundl payment surgeon join hospit
employe transpar price come
pike manag formul new
model orthoped product zimmer could left
dust meantim firm vulner product
recal relat legal fee inventori write-off
regulatori payer push devic registri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
orthoped compani may subject frequent
discoveri product failur subsequ recal
zimmer could also see greater exposur consum
spend pattern increas cost-shar requir
push out-of-pocket expens onto individu patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
zimmer stewardship standard reflect former ceo
david dvorak tenur helm bryan hanson
step ceo role still earli assess
chang firm plan capit alloc
nonetheless fan hanson previou perform
covidien although delv
orthoped market past deep
understand competit dynam medic
technolog good handl hospit client
leadership skill ralli employe base
struggl cultur two legaci compani come
togeth thu far pleas hanson
prioriti systemat approach address myriad
issu hinder zimmer biomet result yet
manifest financi perform
optimist evid improv flow
next month
dvorak leadership zimmer biomet commit
acquir technolog execut number
tuck-in purchas substanti larger purchas
biomet isol event expect
scale acquisit regular basi firm
taken goodwil write-down provid us
measur reassur overpaid
merger acquisit seen hint
manag strateg vision partner close
orthoped surgeon intern innov
small acquisit technolog help practition
address wider span potenti treatment orthoped
patient think may relat david dvorak
tenur ceo began specul
dvorak legal background led stick larg
conserv decis zimmer firm gener
stuck knit focus develop large-joint
replac franchis result zimmer less
prepar take advantag faster growth trauma
extrem compar better
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
wors dvorak tenur heavili color
financi crisi fallout recess push
tradit reconstruct market slower-growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
result
zimmer biomet make measur progress
chang fve apr
consist temper expect full year
leav valuat unchang
firm made substanti progress earlier inventori
issu regulatori hurdl food drug
administr legaci biomet manufactur facil
remain open matter manag expect remedi
effort wrap end year howev fda
work timelin reinspect might take
place despit oper regulatori
turbul hamper zimmer biomet last
two year remain confid firm wide econom
moat remain intact thank primarili high switch cost
practition secondarili consolid vendor
hospit favor zimmer biomet larg pool
zimmer biomet saw report revenu fall year
year substanti foreign currenc headwind muffl
growth constant currenc though zimmer
biomet continu significantli lag behind
built head steam thank mako robot
still saw stronger growth rival johnson johnson
constant currenc beat declin knee
importantli underli volum growth zimmer biomet
larg knee hip -- support
manag content resolv linger
confid underli demand zimmer biomet
implant remain healthi despit recent inventori
quarterli price eros larg joint
slightli higher market though wholli
unexpect zimmer biomet yet reap
reward product mix relat signific adopt
manag
lead
see critic mass rosa robot instal
expect improv price driven shift toward higher-
margin devic consum sold use robot
whole remain optimist rosa
remain earli stage soft launch
confer driven primarili interest rosa robot
receiv total knee replac indic late last
year stark contrast confer
zimmer biomet receiv less lead think
featur rosa fairli distinct
attract practition includ dynam track
allow robot move patient move without
attach patient
firm must priorit manag lead
appropri convert robot sale
hearten see practition interest technolog
think bode well zimmer biomet present strong
competit watch convers lead
next quarter hint well zimmer
biomet abl execut
chang fair valu estim feb
zimmer biomet report fourth-quart perform
demonstr consist increment progress
toward address suppli regulatori cultur
issu hamper firm last two year
unchang full-year
perform gener met expect continu
anticip gradual return growth improv
profit longer term though still think larg
joint growth lag market nonetheless
think new manag method address key
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
largest share knee implant dollar surmis
shift may acut market
mako placement thu particularli
intrigu manag comment suggest zimmer
biomet share loss volum appear less
dollar share loss impli number procedur
use zimmer biomet knee may hold rel
well abl grow knee revenu
sell expens implant portfolio
case zimmer biomet strong posit
roll rosa robot base surgeon alreadi
favor firm product pivot robot-
driven opportun
final look forward see initi clinic data
mako robot upcom orthoped confer
find posit zimmer biomet could see acceler
placement rosa robot year
weak dysfunct sinc ceo bryan hanson join
firm one year ago hanson attent shore
fundament oper leav firm well posit
take advantag wide econom moat stem
issu caught attent come earn
call first firm indic work
remedi plan legaci biomet plant
readi reinspect end year consid
fda first rais issu facil late time
necessari resolv issu move beyond
origin expect two year howev
consider optimist situat
last spring follow fda reinspect
repeat number origin observ longer
time frame remedi suggest zimmer biomet
devot time resourc fulli address regulatori
total knee replac indic rosa robot
weve discuss mako robot
instrument impress knee growth
last two year expect addit rosa zimmer
biomet arsen help firm boost growth
knee franchis first six month soft launch
mute grow strength head
sinc ramp placement mako robot
zimmer biomet johnson johnson born
brunt anem knee sale trail market growth
weve point market share shift
orthoped market tend glacial best due
high switch cost surgeon global basi
estim zimmer biomet lost roughli basi
point market share dollar basi though still own
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
